Algernon Pharmaceuticals: Clinical Stage Drug Development Company
Focused on the disease areas of idiopathic pulmonary fibrosis (IPF) & chronic cough, stroke and chronic kidney disease
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon’s Pipeline and Milestones
For more information on Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) please click the request investor info button.